<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Health, Fondazione Policlinico Universitario A. Gemelli, [5], grid.414603.4National Institute for" exact="Infectious" post="Diseases IRCCS â€œLazzaro Spallanzaniâ€�, [6], 0000 0004 0467 2285grid.419092.7Shanghai"/>
 <result pre="Fondazione Policlinico Universitario A. Gemelli, [5], grid.414603.4National Institute for Infectious" exact="Diseases" post="IRCCS â€œLazzaro Spallanzaniâ€�, [6], 0000 0004 0467 2285grid.419092.7Shanghai Institute"/>
 <result pre="a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the"/>
 <result pre="copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19"/>
 <result pre="of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic."/>
 <result pre="despite great efforts made in almost every country worldwide, this" exact="disease" post="continues to spread globally, especially in most parts of"/>
 <result pre="countries we feel appropriate to evaluate the evolution of the" exact="disease" post="as well as the early result of the treatment,"/>
 <result pre="and unrelated to the size of the country. Subject terms" exact="Viral" post="infection Respiratory tract diseases Facts The Covid-19 pandemic exploded"/>
 <result pre="unrelated to the size of the country. Subject terms Viral" exact="infection" post="Respiratory tract diseases Facts The Covid-19 pandemic exploded first"/>
 <result pre="to the size of the country. Subject terms Viral infection" exact="Respiratory" post="tract diseases Facts The Covid-19 pandemic exploded first in"/>
 <result pre="deaths worldwide as of 25 May 2020, the spread of" exact="infection" post="still seems difficult to contain. Both the availability of"/>
 <result pre="the territory may be responsible for the vast heterogeneity in" exact="infection" post="containment and mortality. Open questions The therapy, especially in"/>
 <result pre="The role of immunity is crucial both to overcame the" exact="acute" post="phase and for establishing the vaccine. Exit from the"/>
 <result pre="acute phase and for establishing the vaccine. Exit from the" exact="acute" post="phase and establishing the new protocol for the post-acute"/>
 <result pre="for the post-acute phase is of utter priority. The severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the"/>
 <result pre="the post-acute phase is of utter priority. The severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19"/>
 <result pre="post-acute phase is of utter priority. The severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 disease"/>
 <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19" exact="disease" post="as originally shown in Wuhan, China, as early as"/>
 <result pre="the entrance of potential COVID-19 cases from China, the first" exact="symptomatic" post="cases have been reported before the end of February"/>
 <result pre="and functionally closely related to the other coronaviruses causing Middle-East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus"/>
 <result pre="functionally closely related to the other coronaviruses causing Middle-East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)."/>
 <result pre="other coronaviruses causing Middle-East respiratory syndrome coronavirus (MERS-CoV) and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV). In particular, it is the"/>
 <result pre="coronaviruses causing Middle-East respiratory syndrome coronavirus (MERS-CoV) and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV). In particular, it is the external"/>
 <result pre="causing Middle-East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV). In particular, it is the external protein"/>
 <result pre="acute respiratory syndrome coronavirus (SARS-CoV). In particular, it is the" exact="external" post="protein of the virus, the glycoprotein spike (S) (Fig."/>
 <result pre="angiotensin-converting enzyme 2 (ACE2), primed by the transmembrane protease serine" exact="type 2" post="(TMPRSS2), and/or CD147 (extracellular matrix metalloproteinase inducer), and therefore"/>
 <result pre="will pave the way for future potential therapeutic interventions. The" exact="viral" post="genomic sequences assembled from samples in Shanghai together with"/>
 <result pre="on Sharing All Influenza Data (GISAID, www.gisaid.org) also showed a" exact="stable" post="evolution (H.L., unpublished data). Based on current data, SARS-CoV-2"/>
 <result pre="rate of around 25 mutations per year, which is much" exact="lower" post="than that of influenza virus7. Therefore, development of effective"/>
 <result pre="glycoprotein. The coronavirus SARS-Cov-2 spike (S) glycoprotein is responsible for" exact="viral" post="entry into the cell and it is the major"/>
 <result pre="is an ectodomain trimer. All three coronaviruses causing severe acuter" exact="respiratory" post="syndrome coronavirus (SARS-Cov), Middle-East respiratory syndrome coronavirus (MERS-CoV), and"/>
 <result pre="an ectodomain trimer. All three coronaviruses causing severe acuter respiratory" exact="syndrome" post="coronavirus (SARS-Cov), Middle-East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2"/>
 <result pre="three coronaviruses causing severe acuter respiratory syndrome coronavirus (SARS-Cov), Middle-East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and SARS-CoV-2 are closely related and"/>
 <result pre="coronaviruses causing severe acuter respiratory syndrome coronavirus (SARS-Cov), Middle-East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and SARS-CoV-2 are closely related and contain"/>
 <result pre="the cells (S1 subunit) and responsible for fusion of the" exact="viral" post="and cellular membrane (S2 subunit). SARS-Cov-2 spike S shows"/>
 <result pre="receptor binding the SARS-Cov-2 virus. The initial step of SARS-Cov-2" exact="viral" post="entry during the infection is the binding of the"/>
 <result pre="virus. The initial step of SARS-Cov-2 viral entry during the" exact="infection" post="is the binding of the viral trimeric spike protein"/>
 <result pre="viral entry during the infection is the binding of the" exact="viral" post="trimeric spike protein (cleaved into S1 and S2 subunits,"/>
 <result pre="countries we feel appropriate to evaluate the evolution of the" exact="disease" post="as well as the early result of the treatment,"/>
 <result pre="median incubation period (interquartile range, 2â€&quot;7) is around 4 days8." exact="Fever" post="is one of the most common symptoms occurring in"/>
 <result pre="60% of the patients8. Gastrointestinal symptoms including nausea, vomiting, and" exact="diarrhea" post="are less frequently developed, with an incidence lower than"/>
 <result pre="vomiting, and diarrhea are less frequently developed, with an incidence" exact="lower" post="than 10% of the patients1,8,9. Other symptoms including rhinorrhoea,"/>
 <result pre="the patients1,8,9. Other symptoms including rhinorrhoea, sore throat, fatigue, dyspnea," exact="muscle" post="weakness, dizziness, and headache are also often reported in"/>
 <result pre="Male 22,981(51.4%) 83 (73%) 67,601 (52.9%) 1304 (82%) 10,062 (67.7%)" exact="Female" post="21691 (48.6%) 30 (27%) 60,189 (47.1%) 287 (18%) 4798"/>
 <result pre="(16.2%) N/A N/A Mild symptoms N/A 18,832 (38.4%) N/A N/A" exact="Severe" post="symptoms 6168 (13.8%) N/A 9416 (19.2%) N/A N/A Critical"/>
 <result pre="specified 257 (0.6%) N/A 7356 (15.0%) N/A N/A Sign symptoms" exact="Fever" post="N/A 104 (92%) N/A N/A 76.0%f Dyspnea N/A 70"/>
 <result pre="N/A N/A 39%f Fatigue N/A 64 (57%) N/A N/A N/A" exact="Diarrhea" post="N/A 27 (24%) N/A N/A 6%f Dizziness and headache"/>
 <result pre="(17.0%) 70 (61.9%) N/A 223 (21%) (hypertension 509 (49%) Ischemic" exact="heart" post="disease: 363 (28.1%); atrial fibrillation: 290 (22.5%); heart failure:"/>
 <result pre="(49%) Ischemic heart disease: 363 (28.1%); atrial fibrillation: 290 (22.5%);" exact="heart" post="failure: 207 (16.0%); stroke: 144 (11.2%); hypertension: 911 (70.6%)"/>
 <result pre="(5.3%) 24 (21.2%) N/A Diabetes: 180 (17%); hypercholesterolemia: 188 (18%)" exact="Type 2" post="diabetes: 409 (31.7%); obesity: 129 (10.0%) Digestive system diseases"/>
 <result pre="(10.0%) Digestive system diseases N/A 1 (0.9%) N/A N/A N/A" exact="Respiratory" post="system diseases 511 (2.4%) 11 (9.7%) N/A COPD^: 42"/>
 <result pre="(2.4%) 11 (9.7%) N/A COPD^: 42 (4%) COPD 234 (18.1%)" exact="Chronic" post="hepatitis B virus infection N/A 5 (4.4%) N/A Chronic"/>
 <result pre="11 (9.7%) N/A COPD^: 42 (4%) COPD 234 (18.1%) Chronic" exact="hepatitis" post="B virus infection N/A 5 (4.4%) N/A Chronic liver"/>
 <result pre="N/A COPD^: 42 (4%) COPD 234 (18.1%) Chronic hepatitis B" exact="virus infection" post="N/A 5 (4.4%) N/A Chronic liver disease: 28 (3%)"/>
 <result pre="COPD^: 42 (4%) COPD 234 (18.1%) Chronic hepatitis B virus" exact="infection" post="N/A 5 (4.4%) N/A Chronic liver disease: 28 (3%)"/>
 <result pre="(18.1%) Chronic hepatitis B virus infection N/A 5 (4.4%) N/A" exact="Chronic" post="liver disease: 28 (3%) Chronic liver disease: 49 (3.8%)"/>
 <result pre="infection N/A 5 (4.4%) N/A Chronic liver disease: 28 (3%)" exact="Chronic" post="liver disease: 49 (3.8%) Chronic kidney disease N/A 4(3.5%)"/>
 <result pre="Chronic liver disease: 28 (3%) Chronic liver disease: 49 (3.8%)" exact="Chronic" post="kidney disease N/A 4(3.5%) N/A 36 (3%) 298 (23.1%)"/>
 <result pre="liver disease: 28 (3%) Chronic liver disease: 49 (3.8%) Chronic" exact="kidney disease" post="N/A 4(3.5%) N/A 36 (3%) 298 (23.1%) Malignant tumor"/>
 <result pre="disease: 28 (3%) Chronic liver disease: 49 (3.8%) Chronic kidney" exact="disease" post="N/A 4(3.5%) N/A 36 (3%) 298 (23.1%) Malignant tumor"/>
 <result pre="Chronic kidney disease N/A 4(3.5%) N/A 36 (3%) 298 (23.1%)" exact="Malignant" post="tumor 107 (0.5%) 1 (0.4%) N/A 81 (8%) 217"/>
 <result pre="kidney disease N/A 4(3.5%) N/A 36 (3%) 298 (23.1%) Malignant" exact="tumor" post="107 (0.5%) 1 (0.4%) N/A 81 (8%) 217 (16.8%)"/>
 <result pre="tumor 107 (0.5%) 1 (0.4%) N/A 81 (8%) 217 (16.8%)" exact="Dementia" post="N/A N/A N/A N/A 203 (15.7%) Autoimmune diseases N/A"/>
 <result pre="(8%) 217 (16.8%) Dementia N/A N/A N/A N/A 203 (15.7%)" exact="Autoimmune" post="diseases N/A 1 (0.4%) N/A N/A 40 (3.1%) Median"/>
 <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and Prevention). bSee ref. 90. cSee ref. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_6-aprile-2020.pdf."/>
 <result pre="91. eSee ref. https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_6_aprile.pdf fAbsolute number not available. Lymphopenia and" exact="leukopenia" post="has been observed in the majority of patients, together"/>
 <result pre="C-reactive protein, lactate dehydrogenase, D-Dimers, and other inflammatory biomarkers, including" exact="tumor" post="necrosis factor-Î± (TNFÎ±), interleukin-1Î² (IL-1Î²), IL-6, granulocyte-macrophage colony-stimulating factor"/>
 <result pre="from early symptoms to dyspnea is around 7 days, while" exact="acute" post="respiratory distress syndrome (ARDS) developed around 9 days1. The"/>
 <result pre="early symptoms to dyspnea is around 7 days, while acute" exact="respiratory" post="distress syndrome (ARDS) developed around 9 days1. The median"/>
 <result pre="to dyspnea is around 7 days, while acute respiratory distress" exact="syndrome" post="(ARDS) developed around 9 days1. The median days of"/>
 <result pre="while 1310 had all symptoms but they were not tested." exact="Disease" post="severity was strongly age dependent, primarily due to the"/>
 <result pre="of patients never have any symptoms or signs, but their" exact="respiratory" post="tract specimens are PCR positive for the virus. The"/>
 <result pre="to represent some 60% of all infections18. Notably, asymptomatic and" exact="symptomatic" post="patients show comparable viral load, suggesting that these patients"/>
 <result pre="of all infections18. Notably, asymptomatic and symptomatic patients show comparable" exact="viral" post="load, suggesting that these patients have strong transmission potentials19."/>
 <result pre="load, suggesting that these patients have strong transmission potentials19. Indeed," exact="viral" post="transmission from asymptomatic carriers have been reported20. In a"/>
 <result pre="al. followed up 2147 close contactors of 191 patients (161" exact="symptomatic" post="and 30 asymptomatic). They found that the infection rates"/>
 <result pre="patients (161 symptomatic and 30 asymptomatic). They found that the" exact="infection" post="rates of transmission rate in symptomatic cases was 6.3%"/>
 <result pre="They found that the infection rates of transmission rate in" exact="symptomatic" post="cases was 6.3% comparing with 4.1% in asymptomatic patients,"/>
 <result pre="antibody testing should be combined with PCR to avoid asymptomatic" exact="viral" post="spreading. Diagnosis of COVID-19 Nucleic acid tests The definitive"/>
 <result pre="of COVID-19 Nucleic acid tests The definitive diagnosis of the" exact="disease" post="relies on the identification of viral genomic RNA using"/>
 <result pre="definitive diagnosis of the disease relies on the identification of" exact="viral" post="genomic RNA using either PCR-based technology or deep sequencing."/>
 <result pre="PCR-based methods have been reviewed elsewhere22. The presence of sufficient" exact="viral" post="genome for amplification at the site of sample collection"/>
 <result pre="a key in diagnosis of the infection. Besides in the" exact="respiratory" post="tract, viral particles have also been detected in the"/>
 <result pre="in diagnosis of the infection. Besides in the respiratory tract," exact="viral" post="particles have also been detected in the blood, lacrimal"/>
 <result pre="tract, viral particles have also been detected in the blood," exact="lacrimal" post="fluid, urine, and feces23,24. In a recent study, the"/>
 <result pre="the PCR test in different types of specimens. As a" exact="viral pneumonia," post="respiratory tract specimens from COVID-19 patients are first of"/>
 <result pre="test in different types of specimens. As a viral pneumonia," exact="respiratory" post="tract specimens from COVID-19 patients are first of choice"/>
 <result pre="are first of choice to collect for the detection of" exact="viral" post="nuclear acid. Collecting and testing upper respiratory specimens would"/>
 <result pre="for the detection of viral nuclear acid. Collecting and testing" exact="upper" post="respiratory specimens would be ideal considering the feasibility in"/>
 <result pre="the detection of viral nuclear acid. Collecting and testing upper" exact="respiratory" post="specimens would be ideal considering the feasibility in clinical"/>
 <result pre="Nasopharyngeal and oropharyngeal swab are the optimal manner for swab" exact="viral" post="testing. These samples can even be collected by patients"/>
 <result pre="earliest days of symptoms, swabs should be collected from the" exact="upper" post="respiratory tract. Recent studies showed that the viral load"/>
 <result pre="days of symptoms, swabs should be collected from the upper" exact="respiratory" post="tract. Recent studies showed that the viral load in"/>
 <result pre="from the upper respiratory tract. Recent studies showed that the" exact="viral" post="load in the upper airway samples peaks within the"/>
 <result pre="tract. Recent studies showed that the viral load in the" exact="upper" post="airway samples peaks within the first week and the"/>
 <result pre="onset in SARS. The dynamic of SARS-CoV-2 shedding in the" exact="lower" post="respiratory tract specimens is still unclear. In MERS, MERS-CoV"/>
 <result pre="in SARS. The dynamic of SARS-CoV-2 shedding in the lower" exact="respiratory" post="tract specimens is still unclear. In MERS, MERS-CoV viral"/>
 <result pre="lower respiratory tract specimens is still unclear. In MERS, MERS-CoV" exact="viral" post="load peaked between week 2 and 3 in lower"/>
 <result pre="MERS-CoV viral load peaked between week 2 and 3 in" exact="lower" post="airways specimens, while the SARS-CoV RNA-positive rates in lower"/>
 <result pre="in lower airways specimens, while the SARS-CoV RNA-positive rates in" exact="lower" post="airways samples remained higher for 3 weeks after beginning"/>
 <result pre="SARS28,29. It is likely that SARS-CoV-2 also shares a comparable" exact="viral" post="shedding pattern in the lower respiratory tract specimens. This"/>
 <result pre="SARS-CoV-2 also shares a comparable viral shedding pattern in the" exact="lower" post="respiratory tract specimens. This may explain why some patients"/>
 <result pre="also shares a comparable viral shedding pattern in the lower" exact="respiratory" post="tract specimens. This may explain why some patients progressed"/>
 <result pre="why some patients progressed despite PCR turned negative in the" exact="upper" post="respiratory specimens8. Despite the high accuracy of the PCR"/>
 <result pre="some patients progressed despite PCR turned negative in the upper" exact="respiratory" post="specimens8. Despite the high accuracy of the PCR tests,"/>
 <result pre="complex, and therefore difficult to be broadly applied in resource" exact="limited" post="locations. Transferring samples to a central laboratory not only"/>
 <result pre="at least at the qualitative level. Moreover, they request very" exact="limited" post="sample volume: one drop of blood from a pinprick"/>
 <result pre="patients who tested IgM/IgG negative in their early phase of" exact="disease" post="could have repeated IgM/IgG tests30, if nucleic acid tests"/>
 <result pre="addition, the serological assays can also provide historic information about" exact="viral" post="exposure, which are important for epidemiology studies. Interestingly, early"/>
 <result pre="tomography The COVID-19 patients presented some typical characteristics on the" exact="chest" post="computed tomography (CT) image. Ground-glass opacity was the most"/>
 <result pre="septal thickening, and thickening of the nearby pleura, with predominantly" exact="lower" post="and peripheral lobe involvement9,35 (Fig. 5). A recent study"/>
 <result pre="and thickening of the nearby pleura, with predominantly lower and" exact="peripheral" post="lobe involvement9,35 (Fig. 5). A recent study by Ai"/>
 <result pre="not available. Nonetheless, not all the patients had the typical" exact="chest" post="CT images (e.g., asymptomatic COVID-19 cases). Absence of CT"/>
 <result pre="had the typical chest CT images (e.g., asymptomatic COVID-19 cases)." exact="Absence of" post="CT or radiographic abnormality was observed in as high"/>
 <result pre="was observed in as high as 17.9% patients with non-severe" exact="disease" post="and in 2.9% cases with severe disease9. Notably, the"/>
 <result pre="of COVID-19 (b) computer tomography of the lung showing a" exact="diffuse" post="interstitial pneumonia. Clinical management At present, there are no"/>
 <result pre="therapeutic protocol is as per best supportive care for any" exact="respiratory" post="disease. However, both antivirals and immune modulators warrant further"/>
 <result pre="antivirals and immune modulators warrant further investigation especially considering the" exact="biphasic" post="pattern of immune responses during the diseases course8. Several"/>
 <result pre="30 Negative 39 Hydroxychloroquine Mild/severe 62 Positive 41 Hydroxychloroquine Symptomatic" exact="disease" post="510 Ongoing https://clinicaltrials.gov/ct2/show/NCT04332991 Hydroxychloroquine Prevention 40,000 Ongoing https://clinicaltrials.gov/ct2/show/NCT04303507 Lopinavir/ritonavir"/>
 <result pre="disease 510 Ongoing https://clinicaltrials.gov/ct2/show/NCT04332991 Hydroxychloroquine Prevention 40,000 Ongoing https://clinicaltrials.gov/ct2/show/NCT04303507 Lopinavir/ritonavir" exact="Severe" post="199 Negative 51 Remdesivir Mild/Moderate 308 Ongoing https://clinicaltrials.gov/ct2/show/NCT04252664 Remdesivir"/>
 <result pre="Severe 199 Negative 51 Remdesivir Mild/Moderate 308 Ongoing https://clinicaltrials.gov/ct2/show/NCT04252664 Remdesivir" exact="Severe" post="453 Negative 59 Remdesivir Severe 2400 Ongoing https://clinicaltrials.gov/ct2/show/NCT04292899 Remdesivir"/>
 <result pre="Mild/Moderate 308 Ongoing https://clinicaltrials.gov/ct2/show/NCT04252664 Remdesivir Severe 453 Negative 59 Remdesivir" exact="Severe" post="2400 Ongoing https://clinicaltrials.gov/ct2/show/NCT04292899 Remdesivir Moderate 1600 Ongoing https://clinicaltrials.gov/ct2/show/NCT04292730 Remdesivir"/>
 <result pre="Moderate 1600 Ongoing https://clinicaltrials.gov/ct2/show/NCT04292730 Remdesivir Moderate/Severe 800 Ongoing https://clinicaltrials.gov/ct2/show/NCT04280705 Dexamethasone" exact="Severe" post="200 Ongoing https://clinicaltrials.gov/ct2/show/NCT04325061 Tocilizumab(IL-6 inhibitor) Severe 20 Positive 84"/>
 <result pre="800 Ongoing https://clinicaltrials.gov/ct2/show/NCT04280705 Dexamethasone Severe 200 Ongoing https://clinicaltrials.gov/ct2/show/NCT04325061 Tocilizumab(IL-6 inhibitor)" exact="Severe" post="20 Positive 84 Tocilizumab Mild/Severe 188 Ongoing http://www.chictr.org.cn/showprojen.aspx?proj=49409 Anakinra"/>
 <result pre="https://clinicaltrials.gov/ct2/show/NCT04330638 Baricitinib (JAK inhibitor) Mild 80 Ongoing https://clinicaltrials.gov/ct2/show/NCT04340232 Convalescent plasma" exact="Severe" post="10 Positive 63 Chloroquine and hydroxychloroquine Chloroquine (CQ) and"/>
 <result pre="which are well-known for their effectiveness in treating malarial and" exact="autoimmune diseases," post="have also recently been repurposed to treat COVID-19. In"/>
 <result pre="to have antiviral activities to different viruses including dengue virus," exact="chikungunya" post="virus, Ebola virus, etc. Any effect found has been"/>
 <result pre="chikungunya virus, Ebola virus, etc. Any effect found has been" exact="limited" post="to in vitro culture. There is no in vivo"/>
 <result pre="especially when combined with azithromycin40. These two studies were both" exact="limited" post="by the small sample size. The U.S. Food and"/>
 <result pre="80 SLE patients who took long-term oral HCQ showed SARS-CoV-2" exact="infection" post="or appeared to have related symptoms. The study found"/>
 <result pre="of the patients in HCQ treatment group showed improvement in" exact="pneumonia" post="compared with the matched controls (54.8%, 17 of 31)."/>
 <result pre="61.3% of patients in the HCQ treated group showed significant" exact="pneumonia" post="absorption. Among the 31 patients in the HCQ treated"/>
 <result pre="modulator and has been used widely for the therapy of" exact="systemic" post="lupus erythematosus or rheumatoid arthritis. It exerts its effects"/>
 <result pre="and has been used widely for the therapy of systemic" exact="lupus erythematosus" post="or rheumatoid arthritis. It exerts its effects likely through"/>
 <result pre="used widely for the therapy of systemic lupus erythematosus or" exact="rheumatoid arthritis." post="It exerts its effects likely through inhibiting the secretion"/>
 <result pre="ARDS development in COVID-19 patients. Thus HCQ application should be" exact="limited" post="to patients who have started to develop or already"/>
 <result pre="immune response at the early stage is critical for controlling" exact="infection" post="and the antiviral effect of HCQ is still in"/>
 <result pre="needed. Needless to say, at late stage of ARDS, controlling" exact="secondary" post="bacterial infection should not take lightly. In addition to"/>
 <result pre="Needless to say, at late stage of ARDS, controlling secondary" exact="bacterial infection" post="should not take lightly. In addition to treatment, CQ/HCQ"/>
 <result pre="to say, at late stage of ARDS, controlling secondary bacterial" exact="infection" post="should not take lightly. In addition to treatment, CQ/HCQ"/>
 <result pre="was reported to be able to reduce the risk of" exact="acute" post="respiratory distress syndrome and mortality in SARS patients45. Meanwhile,"/>
 <result pre="reported to be able to reduce the risk of acute" exact="respiratory" post="distress syndrome and mortality in SARS patients45. Meanwhile, LPV/r"/>
 <result pre="be able to reduce the risk of acute respiratory distress" exact="syndrome" post="and mortality in SARS patients45. Meanwhile, LPV/r and interferon"/>
 <result pre="found to have better efficacy compared with controls for MERS-CoV" exact="infection" post="in animal experiments and case reports46â€&quot;49. LPV/r was therefore"/>
 <result pre="the adenosine analog remdesivir (GS-5734) that is incorporated into nascent" exact="viral" post="RNA chains where it causes a pre-mature termination53. Remdesivir"/>
 <result pre="drug that was generated for the therapy of the Ebola" exact="viral infection." post="Notably, remdesivir has shown antiviral efficacy in treating SARS"/>
 <result pre="SARS-CoV-2-infected rhesus macaques, therapeutic remdesivir treatment was found to reduce" exact="viral" post="load when given early56. In the USA, the first"/>
 <result pre="The recent work elucidating the structure and molecular mechanism of" exact="viral" post="entry4â€&quot;6 showed the specificity of the serine protease inhibitor"/>
 <result pre="as an active compond against TMPRSS2 which is required for" exact="viral infection." post="Camostat mesylate seems rather specific, since SARS-Cov-2 infection requires"/>
 <result pre="for viral infection. Camostat mesylate seems rather specific, since SARS-Cov-2" exact="infection" post="requires TMPRSS2 for the priming of the viral S"/>
 <result pre="since SARS-Cov-2 infection requires TMPRSS2 for the priming of the" exact="viral" post="S protein. Clinical trial of camostat mesylate or its"/>
 <result pre="the neutralizing antibody titers of the patients improved and the" exact="respiratory" post="samples tested negative for SARS-CoV-2 (ref. 62). In another"/>
 <result pre="(ref. 62). In another study of 10 severe cases, the" exact="viral" post="titers were undetectable following the infusion in seven patients"/>
 <result pre="patients who had previously high viremia63. Previous studies on other" exact="respiratory" post="viral diseases provided some evidences on the efficacy of"/>
 <result pre="who had previously high viremia63. Previous studies on other respiratory" exact="viral" post="diseases provided some evidences on the efficacy of convalescent"/>
 <result pre="the efficacy of convalescent plasma on treating severe and critical" exact="viral" post="diseases. Several studies in SARS patients reported that the"/>
 <result pre="especially within 5 days of symptom onset, resulted in a" exact="lower" post="viral load and lower mortality66,67. Subsequent analysis showed that"/>
 <result pre="within 5 days of symptom onset, resulted in a lower" exact="viral" post="load and lower mortality66,67. Subsequent analysis showed that the"/>
 <result pre="of symptom onset, resulted in a lower viral load and" exact="lower" post="mortality66,67. Subsequent analysis showed that the mortality of patients"/>
 <result pre="Subsequent analysis showed that the mortality of patients with severe" exact="acute" post="viral respiratory infections was reduced after therapy with convalescent"/>
 <result pre="analysis showed that the mortality of patients with severe acute" exact="viral" post="respiratory infections was reduced after therapy with convalescent plasma,"/>
 <result pre="showed that the mortality of patients with severe acute viral" exact="respiratory" post="infections was reduced after therapy with convalescent plasma, while"/>
 <result pre="that the mortality of patients with severe acute viral respiratory" exact="infections" post="was reduced after therapy with convalescent plasma, while absence"/>
 <result pre="respiratory infections was reduced after therapy with convalescent plasma, while" exact="absence of" post="adverse events or complications were observed68. Nevertheless, there are"/>
 <result pre="patients had recovered from COVID-19, eligible convalescent plasma is quite" exact="limited" post="as the donors have to pass physical and laboratory"/>
 <result pre="used in critical patients with multiple organ failure, as the" exact="viral" post="load in this kind of population is quite high."/>
 <result pre="in their early phase of diseases. Normally, in COVID-19, the" exact="viral" post="load peaked at the first week of illness, and"/>
 <result pre="in wide contrast. The duration from onset of symptoms to" exact="viral" post="clearance is significantly longer in severe and critical ill"/>
 <result pre="(IL)âˆ’2, IL-7, IL-6, macrophage inflammatory protein 1-Î±, granulocyte-colony stimulating factor," exact="tumor" post="necrosis factor-Î±, and monocyte chemoattractant protein 1 (refs. 1,11)."/>
 <result pre="inflammatory protein 1-Î±, granulocyte-colony stimulating factor, tumor necrosis factor-Î±, and" exact="monocyte" post="chemoattractant protein 1 (refs. 1,11). More importantly, in a"/>
 <result pre="organ dysfunction70,71. The inflammation persists in some patients despite the" exact="viral" post="clearance8,72. Taken together, these evidences support the importance of"/>
 <result pre="the one hand, corticosteroid apparently delay clearance of MERS-CoV from" exact="respiratory" post="tract and SARS-CoV from blood, respectively75,76. On the other"/>
 <result pre="mechanical ventilation although it did not reduce mortality caused by" exact="primary" post="lung infections77. In patients with severe H1N1-illness, low dose"/>
 <result pre="with severe H1N1-illness, low dose of corticosteroids also lead to" exact="lower" post="mortality78. Several clinical trials are now in progress to"/>
 <result pre="to delay of SARS-CoV-2 clearance is still unclear. In some" exact="viral" post="diseases including HIV infection, HCQ administration was associated with"/>
 <result pre="SARS-CoV-2 clearance is still unclear. In some viral diseases including" exact="HIV infection," post="HCQ administration was associated with increased viral replication81. Other"/>
 <result pre="diseases including HIV infection, HCQ administration was associated with increased" exact="viral" post="replication81. Other therapeutic drugs that under investigation include the"/>
 <result pre="rate82. IL-6 inhibitor, which was used as a treatment for" exact="rheumatoid arthritis" post="and CRS associated with CAR-T cell therapies for cancer,"/>
 <result pre="IL-6 inhibitor, which was used as a treatment for rheumatoid" exact="arthritis" post="and CRS associated with CAR-T cell therapies for cancer,"/>
 <result pre="kinase (JAK) in COVID-19 patients target both inflammation and cellular" exact="viral" post="entry85. Recently, a pilot study suggest that JAK inhibitor"/>
 <result pre="that JAK inhibitor is active, well tolerated in patients with" exact="secondary" post="hemophagocytic lymphohistiocytosis indicating these drug maybe apply to COVID-19"/>
 <result pre="JAK inhibitor is active, well tolerated in patients with secondary" exact="hemophagocytic lymphohistiocytosis" post="indicating these drug maybe apply to COVID-19 treatment86. Discharge"/>
 <result pre="be discharged after archive negative PCR results from two continues" exact="respiratory" post="tract specimens, together with defervescence and improvement in radiological"/>
 <result pre="the ICU groups. In critical ill patients, the time of" exact="viral" post="shedding can be as long as 52 days. The"/>
 <result pre="the critical ill patients might be explained by both higher" exact="viral" post="load at baseline and impaired immune responses. In a"/>
 <result pre="impaired immune responses. In a recent study, the mean SARS-CoV-2" exact="viral" post="load of critical ill patients was circa 60 times"/>
 <result pre="times higher than that of moderate cases, indicating that higher" exact="viral" post="loads is linked to severe clinical outcomes87. In addition,"/>
 <result pre="the critical ill patients also showed impaired immunity characterized by" exact="lymphopenia" post="and lower CD4 T cell counts, which were associated"/>
 <result pre="ill patients also showed impaired immunity characterized by lymphopenia and" exact="lower" post="CD4 T cell counts, which were associated with the"/>
 <result pre="T cell counts, which were associated with the duration of" exact="viral" post="shedding8,27. Our cohort in Shanghai showed the median duration"/>
 <result pre="hospital stay was 16 days8,12,20. However, studies have shown that" exact="viral" post="shedding is longer in the feces than in the"/>
 <result pre="viral shedding is longer in the feces than in the" exact="respiratory" post="tract specimens23. More importantly, SARS-CoV-2 isolated from feces was"/>
 <result pre="positive again in a small proportion of patients, although no" exact="infection" post="cases of these close contactors had been reported. Therefore,"/>
 <result pre="Spain, and Germany the increase in number of new SARS-CoV-2" exact="infections" post="has been reducing in recent days, the political measures"/>
 <result pre="89. Assuming, if optimally implemented, that the rate of new" exact="infections" post="caused by an distinct person could be lower than"/>
 <result pre="of new infections caused by an distinct person could be" exact="lower" post="than 1.0, the aforementioned measures might strongly impact in"/>
 <result pre="imposed on public life88. Fig. 6 Daily incidence of new" exact="infections" post="and future scenarios. The Leopoldina Statement reported the daily"/>
 <result pre="The Leopoldina Statement reported the daily incidence of new covid-19" exact="infections" post="in Germany (a blue dots and line) followed by"/>
 <result pre="1). Conversely, the scenario proposes a fast reactivation of the" exact="infections" post="(a, reddish line 2) if the proposed measures fail"/>
 <result pre="South Korea (b), despite full implementation, shows that sporatic new" exact="infections" post="cannot be fully avoided despite serious prevention, resulting in"/>
 <result pre="cannot be fully avoided despite serious prevention, resulting in a" exact="low grade" post="of endemic cases88. Conclusion and way forward After several"/>
 <result pre="and Singapore that such approaches can be feasible, even in" exact="absence of" post="very strict lockdown. Secondly, strengthen health systems capacity in"/>
 <result pre="COVID-19 in Shanghai, ChinaJ. Infect.202080e1e632171869 9.GuanWJet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN. Engl. J. Med.20203821708172032109013 10.ZhouFet al.Clinical course"/>
 <result pre="Med.20203821708172032109013 10.ZhouFet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet202039550751332007143 12.Wu, Z. &amp;amp;"/>
 <result pre="J. M. Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China. JAMA10.1001/jama.2020.2648 (2020) 13.CaiYet al.Pivotal"/>
 <result pre="10.1183/13993003.00547-2020 (2020) 15.SuLet al.The different clinical characteristics of corona virus" exact="disease" post="cases between children and their families in Chinaâ€&quot;the character"/>
 <result pre="Infect.2020970771332208917 16.NishiuraHet al.Estimation of the asymptomatic ratio of novel coronavirus" exact="infections" post="(COVID-19)Int. J. Infect. Dis.20209415415532179137 17.Mizumoto, K., Kagaya, K., Zarebski,"/>
 <result pre="A. &amp;amp; Chowell, G. Estimating the asymptomatic proportion of coronavirus" exact="disease" post="2019 (COVID-19) cases on board the Diamond Princess cruise"/>
 <result pre="Yokohama, Japan, 2020. Eurosurveillance25, 2000180 (2020). 18.Qiu, J. Covert coronavirus" exact="infections" post="could be seeding new outbreaks. Nature10.1038/d41586-020-00822-x (2020) 19.ZouLet al.SARS-CoV-2"/>
 <result pre="infections could be seeding new outbreaks. Nature10.1038/d41586-020-00822-x (2020) 19.ZouLet al.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patientsN. Engl."/>
 <result pre="seeding new outbreaks. Nature10.1038/d41586-020-00822-x (2020) 19.ZouLet al.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patientsN. Engl. J. Med.20203821177117932074444 20.Bai,"/>
 <result pre="new outbreaks. Nature10.1038/d41586-020-00822-x (2020) 19.ZouLet al.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patientsN. Engl. J. Med.20203821177117932074444 20.Bai, Y."/>
 <result pre="transmission of COVID-19. JAMA10.1001/jama.2020.2565 (2020) 21.ChenYet al.The epidemiological characteristics of" exact="infection" post="in close contacts of COVID-19 in Ningbo cityChin. J."/>
 <result pre="types of clinical specimens. JAMA10.1001/jama.2020.3786 (2020). 25.ToKKWet al.Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
 <result pre="specimens. JAMA10.1001/jama.2020.3786 (2020). 25.ToKKWet al.Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect. Dis.20202056557432213337 26.Winichakoon,"/>
 <result pre="J. Clin. Microbiol. 10.1128/JCM.00297-20 (2020). 27.LingYet al.Persistence and clearance of" exact="viral" post="RNA in 2019 novel coronavirus disease rehabilitation patientsChin. Med."/>
 <result pre="al.Persistence and clearance of viral RNA in 2019 novel coronavirus" exact="disease" post="rehabilitation patientsChin. Med. J. (Engl.).20201331039104332118639 28.Al-AbdelyHMet al.Middle east respiratory"/>
 <result pre="coronavirus disease rehabilitation patientsChin. Med. J. (Engl.).20201331039104332118639 28.Al-AbdelyHMet al.Middle east" exact="respiratory" post="syndrome coronavirus infection dynamics and antibody responses among clinically"/>
 <result pre="disease rehabilitation patientsChin. Med. J. (Engl.).20201331039104332118639 28.Al-AbdelyHMet al.Middle east respiratory" exact="syndrome" post="coronavirus infection dynamics and antibody responses among clinically diverse"/>
 <result pre="patientsChin. Med. J. (Engl.).20201331039104332118639 28.Al-AbdelyHMet al.Middle east respiratory syndrome coronavirus" exact="infection" post="dynamics and antibody responses among clinically diverse patients, Saudi"/>
 <result pre="al.Viral shedding patterns of coronavirus in patients with probable severe" exact="acute" post="respiratory syndromeLancet20043631699170015158632 30.GuoLet al.Profiling early humoral response to diagnose"/>
 <result pre="shedding patterns of coronavirus in patients with probable severe acute" exact="respiratory" post="syndromeLancet20043631699170015158632 30.GuoLet al.Profiling early humoral response to diagnose novel"/>
 <result pre="syndromeLancet20043631699170015158632 30.GuoLet al.Profiling early humoral response to diagnose novel coronavirus" exact="disease" post="(COVID-19)Clin. Infect. Dis.202010.1093/cid/ciaa31032497196 31.Sheridan, C. Fast, portable tests come"/>
 <result pre="https://www.medrxiv.org/content/10.1101/2020.04.14.20059733v1 (2020). 35.ShiHet al.Radiological findings from 81 patients with COVID-19" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet Infect. Dis.20202042543432105637 36.Ai,"/>
 <result pre="descriptive studyLancet Infect. Dis.20202042543432105637 36.Ai, T. et al. Correlation of" exact="chest" post="CT and RT-PCR testing in coronavirus disease 2019 (COVID-19)"/>
 <result pre="al. Correlation of chest CT and RT-PCR testing in coronavirus" exact="disease" post="2019 (COVID-19) in China: a report of 1014 cases."/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 10.1093/cid/ciaa237"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 10.1093/cid/ciaa237 (2020)."/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 10.1093/cid/ciaa237 (2020). 39.Chen,"/>
 <result pre="Shabani, M., Shokouhi, S. &amp;amp; Saffaei, A. Aminoquinolines against coronavirus" exact="disease" post="2019 (COVID-19): chloroquine or hydroxychloroquine. Int. J. Antimicrob. Agents55,105945"/>
 <result pre="COVID-19. Lancet Infect. Dis. 10.1016/s1473-3099(20)30296-6 (2020). 45.ChanKSet al.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
 <result pre="Lancet Infect. Dis. 10.1016/s1473-3099(20)30296-6 (2020). 45.ChanKSet al.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
 <result pre="Infect. Dis. 10.1016/s1473-3099(20)30296-6 (2020). 45.ChanKSet al.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
 <result pre="46.KimUJWonEJKeeSJJungSIJangHCCombination therapy with lopinavir/ritonavir, ribavirin and interferon-a for Middle East" exact="respiratory" post="syndromeAntivir. Ther.20162145545926492219 47.MinCKet al.Comparative and kinetic analysis of viral"/>
 <result pre="East respiratory syndromeAntivir. Ther.20162145545926492219 47.MinCKet al.Comparative and kinetic analysis of" exact="viral" post="shedding and immunological responses in MERS patients representing a"/>
 <result pre="immunological responses in MERS patients representing a broad spectrum of" exact="disease" post="severitySci. Rep.201662535927146253 48.SpanakisNet al.Virological and serological analysis of a"/>
 <result pre="48.SpanakisNet al.Virological and serological analysis of a recent Middle East" exact="respiratory" post="syndrome coronavirus infection case on a triple combination antiviral"/>
 <result pre="al.Virological and serological analysis of a recent Middle East respiratory" exact="syndrome" post="coronavirus infection case on a triple combination antiviral regimenInt."/>
 <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt. J. Antimicrob."/>
 <result pre="et al. Efficacy and safety of lopinavir/ritonavir or arbidol in" exact="adult" post="patients with mild/moderate COVID-19: an exploratory randomizedcontrolled trial. Med."/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ."/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ. Infect. Dis.2015211809025030060"/>
 <result pre="from Wuhan, China. Intensive Care Med. 10.1007/s00134-020-05991-x (2020). 70.LiGet al.Coronavirus" exact="infections" post="and immune responsesJ. Med. Virol.20209242443231981224 71.LuRet al.Genomic characterisation and"/>
 <result pre="host-directed therapies should be an optionLancet2020395e35e3632035018 73.PeirisJSMet al.Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
 <result pre="75.ArabiYMet al.Corticosteroid therapy for critically ill patients with middle east" exact="respiratory" post="syndromeAm. J. Respir. Crit. Care Med.201819775776729161116 76.LeeNet al.Effects of"/>
 <result pre="early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in" exact="adult" post="patientsJ. Clin. Virol.20043130430915494274 77.DellingerRPet al.Surviving sepsis campaign: international guidelines"/>
 <result pre="on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09" exact="viral" post="pneumoniaInfluenza Other Respi. Viruses201711345354 79.ZhouWet al.Potential benefits of precise"/>
 <result pre="Rev. Rheumatol.20201615516632034323 81.PatonNIet al.Effects of hydroxychloroquine on immune activation and" exact="disease" post="progression among HIV-infected patients not receiving antiretroviral therapy: A"/>
 <result pre="Med.20164427528126584195 83.National Health Commission of China. Diagnosis and treatment of" exact="pneumonia" post="caused by 2019 new coronavirus (trial version 7). http://www.gov.cn/zhengce/zhengceku/2020-03/04/5486705/files/ae61004f930d47598711a0d4cbf874a9.p"/>
 <result pre="Acad. Sci. USA2020117109701097532350134 85.RichardsonPet al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet2020395e30e3132032529 86.AhmedAet al.Ruxolitinib in adult patients with secondary"/>
 <result pre="Sci. USA2020117109701097532350134 85.RichardsonPet al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet2020395e30e3132032529 86.AhmedAet al.Ruxolitinib in adult patients with secondary haemophagocytic"/>
 <result pre="potential treatment for 2019-nCoV acute respiratory diseaseLancet2020395e30e3132032529 86.AhmedAet al.Ruxolitinib in" exact="adult" post="patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot"/>
 <result pre="2019-nCoV acute respiratory diseaseLancet2020395e30e3132032529 86.AhmedAet al.Ruxolitinib in adult patients with" exact="secondary" post="haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialLancet Haematol.20196e630e63731537486 87.Liu,"/>
 <result pre="an open-label, single-centre, pilot trialLancet Haematol.20196e630e63731537486 87.Liu, Y. et al." exact="Viral" post="dynamics in mild and severe cases of COVID-19. Lancet"/>
 <result pre="(2020). 90.ChenTet al.Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective studyBMJ2020368m109132217556 91.GrasselliGet al.Baseline characteristics and outcomes of"/>
</results>
